Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 3/20 | 0.52 |
| ▸ | PGK2 | P07205 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489198 | 0.81 | PGK1 (0.47) | PGK1PGK2CYP3A4HTTL3MBTL1 | |
| SCHEMBL2637100 | 0.81 | PGK1 (0.43) | PGK1PGK2HTTL3MBTL1 | |
| SCHEMBL11066106 | 0.80 | LMNA (0.44) | PGK1PGK2 | |
| SCHEMBL11310785 | 0.78 | HTT (0.64) | TAAR1MMP2MMP9MMP12HTT | |
| SCHEMBL2864893 | 0.78 | SLC5A1 (0.46) | PGK1PGK2CYP3A4 | |
| SCHEMBL23363997 | 0.77 | PGK1 (0.40) | PGK1PGK2L3MBTL1 | |
| SCHEMBL9282437 | 0.77 | GAA (0.51) | PGK1PGK2TAAR1HTR2AHTT | |
| SCHEMBL2637341 | 0.77 | PGK1 (0.40) | PGK1PGK2CYP3A4TAAR1HTT | |
| SCHEMBL8113848 | 0.76 | MAPT (0.53) | CYP3A4 | |
| SCHEMBL2864690 | 0.74 | CA2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221180-A1 | IN VIVO IMAGING OF MYELINATION | WANG YANMING | 2010-09-02 | — | — | US | disclosed |
| EP-2198040-A1 | IN VIVO IMAGING OF MYELIN | Case Western Reserve University (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009029936-A1 | IN VIVO IMAGING OF MYELIN | CASE WESTERN RESERVE UNIVERSITY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221180-A1 | IN VIVO IMAGING OF MYELINATION | MAG, PMP22, MYT1 | PGK1 4157/4885PGK2 3772/4885CYP3A4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.